CHROMADEX ..(Ticker INDEX) ..inside

Kosmonova buran

In 2004, Dr. Charles Brenner, then a faculty member at Dartmouth College, discovered NR to be a vitamin precursor of nicotinamide adenine dinucleotide (NAD+) found in milk, which is made available by nicotinamide riboside kinases (Nrks) that are conserved between yeast and humans. In 2007, Dr. Brenner's lab discovered a second pathway by which NR is converted to NAD+ and showed that NR can extend the lifespan of yeast cells by virtue of elevating NAD+ levels and increasing the activity of the NAD+ dependent Sir2 enzyme. In the past decade, Dr. Brenner has made multiple, seminal contributions to NAD+ metabolism, which included engineering a yeast strain to convert inexpensive NAD+ precursor vitamins into NR, identifying a high affinity NR transporter, solving the crystal structure of human Nrk1, and developing the methods for quantitative NAD+ metabolomics. Dr. Brenner's gene discoveries and characterization of the NAD+ metabolome have shed light on distinct pathways by which human cells utilize distinct NAD+ precursor vitamins. His lab continues to focus on characterizing the molecular mechanisms underlying NAD+ precursors and their impact on human health. Groups worldwide have added to Dr. Brenner's discoveries in providing evidence for unique properties of NR in neuroprotection, sirtuin activation, protection against weight gain on a high fat diet, and improvement of blood glucose and insulin sensitivity.

Dr. Brenner, now the Roy J. Carver Chair and Head of Biochemistry at the University of Iowa and Founding Co-Director of the University of Iowa Obesity Initiative, commented, "NR has great potential both as a nutritional supplement as well as a therapeutic product for specific diseases and conditions. While more research is needed to develop NR as a potentially safe and effective human therapeutic, this developmental path would not be possible without good licensing partners. We are very pleased that ChromaDex has made development of NR a priority."

Alla Kan, Director of Technology Transfer at Dartmouth, stated, "This expansion of our successful collaboration with ChromaDex provides new venues for NR utilization in healthcare. This license is a perfect example of the benefits to society created by the technology transferred from academia to industry. We look forward to developing NR for human therapies."

Frank Jaksch, CEO and Founder of ChromaDex, stated, "The acquisition of these additional Dartmouth patent rights allows for ChromaDex to commercialize NR as a drug.  Together with our existing patent portfolio pertaining to NR, we believe our ownership of these new patent rights creates a significant and meaningful barrier to entry for would-be competitors in the entire NAD+ precursor market."

About Nicotinamide Riboside (NR):

Sometimes referred to as the "Miracle Molecule" or "Hidden Vitamin," NR is found naturally in trace amounts in milk and other foods and is a more potent, no-flush version of Niacin (vitamin B3).  Published research has shown that NR is perhaps the most effective NAD+ booster, an essential metabolite found in all cells. NAD+ is arguably the most important cellular co-factor for improvement of mitochondrial performance and energy metabolism. Mitochondria are the powerhouse of the cell where macronutrients are converted to energy the cell can use. Mitochondria also play an important part in the aging process. It is hoped that by stimulating mitochondrial function with the NR molecule, scientists may see increased longevity as well as other health improvements. Researchers worldwide continue seminal discoveries characterizing the unique properties of NR in a wide range of health benefits. These include: increasing mitochondrial health, increasing muscle endurance, neuroprotection, sirtuin activation, protection against weight gain on high fat diet, protection against oxidative stress, improvement of blood glucose and insulin sensitivity. In recent years, NAD+ has also been recognized as an extracellular signaling molecule involved in cell-to-cell communication.

A study by researchers from Harvard Medical School in conjunction with the National Institute on Aging was published in December 2013 in CELL demonstrated that mitochondrial dysfunction (a hallmark of ageing) in ageing mice is due to a disruption in Sirtuin1-dependent nuclear-mitochondrial communication. They further show that a reduction in NAD+ levels is responsible for this disruption. Excitingly, they also show that this mitochondrial dysfunction is readily reversible by administration of a NAD+ precursor. The authors show that "1 week of treatment with a compound that boosts NAD+ levels is sufficient to restore the mitochondrial homeostasis and key biochemical markers of muscle health in a 22-month-old mouse to levels similar to a 6-month-old mouse."

Separately, findings from a 2012 study conducted by researchers at Weill Cornell Medical College and the Ecole Polytechnique Federale de Lausanne, Switzerland researchers showed mice on a high-fat diet that were fed NR gained 60 percent less weight than mice eating the same high-fat diet without NR. Moreover, unlike the mice that were not fed NR, none of the NR-treated mice had indications that they were developing diabetes and they had improved energy and lower cholesterol levels, all without side effects. The Swiss researchers were quoted as saying the effects of NR on metabolism "are nothing short of astonishing."

About Dartmouth College:

Established in 1769 and a member of the Ivy League, Dartmouth is a superb undergraduate residential college with the intellectual character of a university, featuring thriving research and first-rate graduate and professional programs. The quality of the undergraduate experience is enhanced by close student-faculty interaction, opportunities for independent research, a broad range of off-campus programs, and a diverse student body. Graduate programs include Geisel School of Medicine, graduate programs in the Arts and Sciences, Thayer School of Engineering, and the Tuck School of Business.

About ChromaDex:

ChromaDex is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes pTeroPure® pterostilbene; ProC3G®, a natural black rice containing cyanidin-3-glucoside; PURENERGY®, a caffeine-pTeroPure® co-crystal; and NIAGEN™, its recently launched branded nicotinamide riboside, a novel next-generation B vitamin. To learn more about ChromaDex, visit www.chromadex.com.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's Annual Report on Form 10-K for the fiscal year ended December 28, 2013, the Company's Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

ChromaDex Media Inquiries:                                                

Beckerman PR

Jerry Schranz

201-465-8020        

jschranz@beckermanpr.com                                                                                

ChromaDex Company Contact:

Laura Kelly, Executive Assistant

949-419-0288

laurak@chromadex.com

SOURCE ChromaDex Corporation


Quelle: PR Newswire

"St. Jude is a pioneer in the development of therapies to fight pediatric catastrophic diseases, and with this partnership, we will work to help support their important work," said Frank L. Jaksch, Jr., founder and CEO of ChromaDex. "The ChromaDex catalog offers thousands of unique phytochemical compounds, many of which have never been investigated for their therapeutic potentials. We are excited to start this collaboration with St. Jude, as this program will not only allow ChromaDex to extract value from the natural products library, but also advance pediatric disease research."

About St. Jude Children's Research Hospital:  

St. Jude Children's Research Hospital is internationally recognized for its pioneering research and treatment of children with cancer and other life-threatening diseases. The hospital has played a pivotal role in pushing overall U.S. pediatric cancer survival rates from 20 to 80 percent. Founded by the late entertainer Danny Thomas, St. Jude is the first and only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. St. Jude is also a leader in research and treatment of life-threatening blood disorders and infectious diseases in children. To learn more, visit www.stjude.org.

About ChromaDex:

ChromaDex is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes pTeroPure® pterostilbene; ProC3G®, a natural black rice containing cyanidin-3-glucoside; PURENERGY™, a caffeine-pTeroPure co-crystal; and NIAGEN™, its recently launched branded nicotinamide riboside, a novel next-generation B vitamin. To learn more about ChromaDex, visit www.chromadex.com.

Forward-Looking Statements:

Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

ChromaDex Media Inquiries:

Beckerman PR

Jerry Schranz

201-465-8020

jschranz@beckermanpr.com                                                                                                                                        

ChromaDex Company Contact:

Laura Kelly, Executive Assistant

949-419-0288

laurak@chromadex.com

Statements in this press release have not been evaluated by the Food and Drug Administration.  Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.

SOURCE ChromaDex Corp.


Quelle: PR Newswire

Kornberg's father, the late Arthur Kornberg, was a professor of biochemistry at Stanford and was awarded the Nobel Prize for physiology or medicine in 1959. He was among the first to investigate nicotinamide riboside more than 60 years while at the NIH.

Kornberg commented, "Given my father's noteworthy early research of nicotinamide riboside, I have been following ChromaDex's progress on developing its NIAGEN™ nicotinamide riboside as well as the enormous amount of published research that speaks to the health benefits of NR. I look forward to working with the other members of the SAB as well as the Company's management."

Dr. Phillip Frost, Chairman and Chief Executive Officer of Opko Health, Inc. (NYSE: OPK) commented, "As both Opko Health and I are substantial investors in ChromaDex, I am very pleased to see Roger Kornberg become the Chair of ChromaDex's new SAB."        

Frank Jaksch, Jr., founder and CEO of ChromaDex, commented, "We are honored to have Roger Kornberg Chair our recently formed SAB. His outstanding scientific achievements and extensive experience serving on the Boards of other pharma and biotech companies will be valuable as we progress with the development and commercialization of our novel ingredient pipeline, including NR."

About ChromaDex:

ChromaDex is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes pTeroPure® pterostilbene; ProC3G®, a natural black rice containing cyanidin-3-glucoside; PURENERGY®, a caffeine-pTeroPure® co-crystal; and NIAGEN™, its recently launched branded nicotinamide riboside, a novel next-generation B vitamin. To learn more about ChromaDex, visit www.chromadex.com.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's Annual Report on Form 10-K for the fiscal year ended December 28, 2013, the Company's Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

ChromaDex Media Inquiries:                        

Beckerman PR

Jerry Schranz

201-465-8020

jschranz@beckermanpr.com    

ChromaDex Company Contact:

Laura Kelly, Executive Assistant

949-419-0288

laurak@chromadex.com

These statements have not been evaluated by the Food and Drug Administration.  These products or ingredients are not intended to diagnose, treat, cure or prevent any disease.

SOURCE ChromaDex Corporation


Quelle: PR Newswire

Published research has shown that NR is perhaps the most effective precursor to boost the co-enzyme NAD+ in the cell.  NAD+ is arguably the most important cellular co-factor for improvement of mitochondrial performance and energy. In recent years, NAD+ has also been shown to participate as an extracellular signaling molecule in cell-to-cell communication.  NAD+ is essential in supporting healthy cellular metabolism including the efficient conversion of blood glucose into energy.

As organisms age, NAD+ levels drop, which leads to a decrease in mitochondrial health; this in turn leads to age-related health issues. Low NAD+ levels limit activity of a group of enzymes called sirtuins, which are believed to play a key role in longevity. NAD+ levels can be depleted by lifestyle choices such as overeating and lack of exercise. By boosting NAD+, NR can increase mitochondrial health and induce creation of new mitochondria.

Frank Jaksch, Jr., founder and CEO of ChromaDex, commented, "The primary goal of this human study is to confirm previous published research in animals showing that NR is an effective precursor to NAD+. Confirming that NR leads to a meaningful increase in NAD+ metabolites in humans is perhaps the single most important clinical endpoint in proving that NR will have significant impact on human health."

Jaksch continued, "Confirming that NR leads to a meaningful increase in NAD+ in humans should also be an incredible driver with respect building consumer awareness for NIAGEN™ as well as increased interest for the ingredient by both consumer products companies as well as pharmaceutical companies interested in therapeutic applications of  NIAGEN™."

ChromaDex's NIAGEN™ is supported by five patents issued and several pending, with patents rights acquired from Cornell University, Dartmouth College and Washington University. In addition to the human clinical study, ChromaDex is actively collaborating with numerous leading universities and research institutes on the health benefits of NIAGEN™, including a recent partnership with Wageningen University in the Netherlands.

About Nicotinamide Riboside (NR):

Sometimes referred to as the "hidden vitamin," NR is found naturally in trace amounts in milk and other foods and is a more potent, no-flush version of Niacin (vitamin B3).  Published research has shown that NR is perhaps the most effective booster of NAD+, an essential metabolite found in all cells. NAD+ is arguably the most important cellular co-factor for the improvement of mitochondrial performance and energy metabolism. Mitochondria are the powerhouses of the cell where macronutrients are converted to energy the cell can use. Mitochondria also play an important part in the aging process. Scientists hope that the stimulation of mitochondrial function with NR may result in increased longevity as well as other health improvements. Researchers worldwide are continuing to make seminal discoveries characterizing the unique properties of NR in a wide range of health benefits. These include increased mitochondrial health, increased muscle endurance, neuroprotection, sirtuin activation, protection against weight gain on high-fat diet, protection against oxidative stress and improvement of blood glucose and insulin sensitivity.

A study by researchers from Harvard Medical School in conjunction with the National Institute on Aging  published in December 2013 in Cell demonstrated that mitochondrial dysfunction (a hallmark of aging) in aging mice is due to a disruption in Sirtuin1-dependent nuclear-mitochondrial communication. The study further showed that a reduction in NAD+ levels is responsible for this disruption. Excitingly, the study demonstrated that this mitochondrial dysfunction is readily reversible by the administration of a NAD+ precursor. The study reported that "1 week of treatment with a compound that boosts NAD+ levels is sufficient to restore the mitochondrial homeostasis and key biochemical markers of muscle health in a 22-month-old mouse to levels similar to a 6-month-old mouse," indicating that some aspects of aging may be theoretically reversible.

Separately, findings from a 2012 study conducted by researchers at Weill Cornell Medical College and the Ecole Polytechnique Federale de Lausanne , Switzerland  showed that mice on a high-fat diet which were fed NR gained 60 percent less weight than mice eating the same high-fat diet without NR. Moreover, unlike the mice that were not fed NR, none of the NR-treated mice had indications that they were developing diabetes and their energy and lower cholesterol levels improved, all without side effects. The Swiss researchers were quoted as saying the effects of NR on metabolism were "nothing short of astonishing."

About ChromaDex:

ChromaDex is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes pTeroPure® pterostilbene; ProC3G®, a natural black rice containing cyanidin-3-glucoside; PURENERGY®, a caffeine-pTeroPure® co-crystal; and NIAGEN™, its recently launched branded nicotinamide riboside, a novel next-generation B vitamin. To learn more about ChromaDex, visit www.chromadex.com.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's Annual Report on Form 10-K for the fiscal year ended December 28, 2013, the Company's Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

ChromaDex Media Inquiries:  

Beckerman PR

Jerry Schranz

201-465-8020                                                                            

jschranz@beckermanpr.com  

ChromaDex Company Contact:

Laura Kelly, Executive Assistant

949-419-0288

laurak@chromadex.com

These statements have not been evaluated by the Food and Drug Administration.  These products or ingredients are not intended to diagnose, treat, cure or prevent any disease.

SOURCE ChromaDex


Quelle: PR Newswire

company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes pTeroPure® pterostilbene; ProC3G®, a natural black rice containing cyanidin-3-glucoside; PURENERGY®, a caffeine-pTeroPure® co-crystal; and NIAGEN™, its recently launched branded nicotinamide riboside, a novel next-generation B vitamin. To learn more about ChromaDex, visit www.chromadex.com.

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's Annual Report on Form 10-K for the fiscal year ended December 28, 2013, the Company's Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

ChromaDex Media Inquiries:  

Beckerman PR

Jerry Schranz

201-465-8020                                                                            

jschranz@beckermanpr.com  

ChromaDex Company Contact:

Laura Kelly, Executive Assistant

949-419-0288

laurak@chromadex.com

These statements have not been evaluated by the Food and Drug Administration.  These products or ingredients are not intended to diagnose, treat, cure or prevent any disease.

SOURCE ChromaDex


Quelle: PR Newswire

Index Membership: N/A
   Sector:§Basic Materials
 Industry:§Chemicals - Major Diversified
Full Time Employees: 63
finance.yahoo.com/q/pr?s=CDXC

Primary IR Contact
The Del Mar Consulting Group, Inc.
Robert B. Prag, President
858-794-9500
bprag@delmarconsulting.com


ChromaDex Contact:
Laura Kelly, Executive Assistant
949-419-0288
laurak@chromadex.com
investors.chromadex.com/...x.zhtml?c=212121&p=irol-contact

investors.chromadex.com/...x.zhtml?c=212121&p=irol-infoReq GrB

You can quickly assemble your own Investor Kit by selecting and printing from the following documents. To order printed materials, or request additional investor-related information, complete an information request.
Latest Corporate Presentation
Current Earnings Release
2014 Q1 Quarterly Report on Form 10Q
2013 Annual Report on Form 10K
Pterostilbene Clinical Study Data
You may also find news of interest to investors on our Press Releases page.
investors.chromadex.com/...tml?c=212121&p=irol-investorKit

Q1 Earnings Release on 5/8/2014
Download Documentation Earnings Press Release
Download Documentation Form 10Q

Q4 Earnings Release on 3/27/2014
Download Documentation Earnings Press Release
Download Documentation Form 10K

Q3 Earnings Release on 11/21/2013
Download Documentation Earnings Press Release
Download Documentation Form 10Q

Q2 2013 Results
Download Documentation Form 10Q

Q1 2013 Results
Download Documentation Form 10Q

Q4 Earnings Release on 3/29/2013
Download Documentation Earnings Press Release
Download Documentation Form 10K

Q3 Earnings Release on 11/8/2012
Download Documentation Earnings Press Release
Download Documentation Form 10Q

Q2 Earnings Release on 08/9/2012
Download Documentation Earnings Press Release
Download Documentation Form 10Q

Q1 Earnings Release on 05/10/2012
Download Documentation Earnings Press Release
Download Documentation Form 10Q

Q4 Earnings Release on 03/15/2012
Download Documentation Earnings Press Release
Download Documentation Form 10K

Q3 Earnings Release on 11/10/2011
Download Documentation Earnings Press Release
Download Documentation Form 10Q

Q2 Earnings Release on 08/11/2011
Download Documentation Earnings Press Release
Download Documentation Form 10Q

Q1 Earnings Release on 05/11/2011
Download Documentation Earnings Press Release
Download Documentation Form 10Q


Q4 Earnings Release on 03/16/2011
Download Documentation Earnings Press Release
Download Documentation Form 10K


Q3 Earnings Release on 11/16/2010
Download Documentation Earnings Press Release
Download Documentation Form 10Q


Q2 Earnings Release on 08/17/2010
Download Documentation Earnings Press Release
Download Documentation Form 10Q
investors.chromadex.com/...ml?c=212121&p=quarterlyEarnings

Download Documentation 2014 Q1 Quarterly Report on Form 10Q
Download Documentation 2013 Annual Report on Form 10K
Download Documentation ChromaDex Corporate Presentation
Download Documentation 2012 Annual Report on Form 10K
Download Documentation 2012 Proxy Statement & 2011 Annual Report
Download Documentation 2011 Proxy Statement & 2010 Annual Report
Download Documentation 2010 Proxy Statement & 2009 Annual Report
Download Documentation 2009 Proxy Statement & 2008 Annual Report
investors.chromadex.com/...l?c=212121&p=irol-reportsAnnual

Firm Analyst Phone E-Mail
Aegis Capital Corp Yi Chen, Ph.D. 646-502-2463 ychen@aegiscap.com
Raghuram Selvaraju, Ph.D. 646-502-2464 rselvaraju@aegiscap.com
Dawson James Securities Robert M. Wasserman 561-208-2905 rwasserman@dawsonjames.com
investors.chromadex.com/....zhtml?c=212121&p=irol-analysts

  06/27/14         4§Statement of changes in beneficial ownership of securities 3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
  06/27/14         4§Statement of changes in beneficial ownership of securities 3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
  06/27/14         4§Statement of changes in beneficial ownership of securities 3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
  06/27/14         4§Statement of changes in beneficial ownership of securities 3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
  06/27/14         4§Statement of changes in beneficial ownership of securities 3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
investors.chromadex.com/phoenix.zhtml?c=212121&p=irol-sec

Valuation
P/E (TTM) --
Price to Revenue (TTM) 13.44
Price to Cash Flow (TTM) --
Price to Book (MRQ) 30.10
investors.chromadex.com/...html?c=212121&p=irol-fundratios

Revenue/Share (TTM) .11
EPS Fully Diluted (TTM) -.05
Dividend/Share (TTM) --
Book Value/Share (MRQ) .05
Cash Flow/Share (TTM) -.04
Cash (MRQ) .02
investors.chromadex.com/...html?c=212121&p=irol-fundratios

Operating Margin (TTM) (%) -44.11
Net Profit Margin (TTM) (%) -44.43
Gross Margin (TTM) (%) 31.61
investors.chromadex.com/...html?c=212121&p=irol-fundratios

5 Year Annual Growth (%) -8.58
5 Year Annual Revenue Growth Rate (%) 17.66
5 Year Annual Dividend Growth Rate (%) --
5 Year EPS Growth (%) --
investors.chromadex.com/...html?c=212121&p=irol-fundratios

Quick Ratio (MRQ) 1.21
Current Ratio (MRQ) 1.98
LT Debt to Equity (MRQ) (%) 5.21
Total Debt to Equity (MRQ) (%) 8.05
investors.chromadex.com/...html?c=212121&p=irol-fundratios

Return on Equity (TTM) (%) -112.17
Return on Assets (TTM) (%) -59.44
Return on Investment (TTM) (%) -102.89
investors.chromadex.com/...html?c=212121&p=irol-fundratios

Asset Turnover (TTM) 1.34
Inventory Turnover (TTM) 3.67
investors.chromadex.com/...html?c=212121&p=irol-fundratios

investors.chromadex.com/....zhtml?c=212121&p=irol-calendar GrB

ChromaDex Corp at Jefferies Global Healthcare Conference
Tuesday, June 3, 2014 2:00 p.m. ET
  Location§New York, NY US

ChromaDex Corp at B. Riley & Co. Investor Conference
Monday, May 19, 2014 12:30 p.m. ET
  Location§Loews Santa Monica
Santa Monica, CA US

ChromaDex Corp at ROTH Conference
Monday, March 10, 2014 4:30 p.m. PT
  Location§Orange, CA US

ChromaDex Corp at Roth Conference
Tuesday, March 19, 2013 5:30 p.m. PT
  Location§Dana Point, CA

ChromaDex Corp at RedChip Small-Cap Virtual Conference
Wednesday, December 5, 2012 2:45 p.m. ET
investors.chromadex.com/...ml?c=212121&p=irol-calendarpast

  04/23/14§UM Technology Management Division and Research Partners Land National Award Printer Friendly Version
  04/16/14§ChromaDex CEO, Frank Jaksch, to Speak at 13th Annual Oxford International Conference on the Science of Botanicals
Printer Friendly Version
  04/15/14§ChromaDex Signs Material Transfer Agreement With University of Copenhagen for NIAGEN™ Nicotinamide Riboside Research
Printer Friendly Version
  04/07/14§ChromaDex Signs Collaboration Research Agreement with Brazilian Research Institute
Printer Friendly Version
  04/02/14§Thorne Research Introduces a New Product, NiaCel™, Featuring NIAGEN™, To Support Healthy Aging
Printer Friendly Version
  03/27/14§ChromaDex® Reports 2013 Full-Year Results
Printer Friendly Version
  03/12/14§ChromaDex Signs Material Transfer Agreement With Leading Dutch University for NIAGEN™ Research
Printer Friendly Version
  03/06/14§ChromaDex to Present at the 26th Annual ROTH Conference on March 10th at 4:30 pm PDT
Printer Friendly Version
  01/06/14§ChromaDex® Announces $62 Million Ingredient Agreement with Network Marketing Company 5LINX® Printer Friendly Version
  01/03/14§ChromaDex® Appoints Former Nestle Executive to Its Board of Directors
Printer Friendly Version
investors.chromadex.com/...?c=212121&p=irol-news&nyo=0

Top Holders
Shares Held % O/S Share Change Filing Date
Frost Phillip MD ET AL 15,252,937 14.4 0 03/20/14
Brauser (Michael H) 8,491,350 8.0 2,235,712 03/20/14
Honig (Barry C) 8,215,216 7.7 365,200 03/20/14
Black Sheep, FLP 6,225,155 5.9 0 03/20/14
Fidelity Management & Research Company 2,191,466 2.1 -147,500 05/31/14
Germain (Margery) 2,053,995 1.9 0 03/20/14
Jaksch (Frank Louis Jr) 2,018,165 1.9 250,000 03/20/14
Halpryn (Glenn L) 1,281,428 1.2 10,000 03/20/14
Varvaro (Thomas C) 503,500 0.5 250,000 03/20/14
AMG National Trust Bank 67,995 0.1 15,625 03/31/14

Top Holders: Mutual Funds
Shares % O/S Share Change Filing Date
Fidelity Select Biotechnology Portfolio 2,047,600 1.9 -147,500 05/31/14
Fidelity Advisor Biotechnology Fund 143,866 0.1 0 05/31/14
investors.chromadex.com/...=212121&p=irol-ownershipSummary

Exchange OTC BB (US Dollar)
     Price§$1.38
Change (%) Stock is Down 0.02 (1.43%)
    Volume§76,508
Today's Open $1.38
Previous Close $1.40
Intraday High $1.40
Intraday Low $1.33
52 Week High $2.15
52 Week Low $0.65
Data as of 07/18/14 4:00 p.m. ET
investors.chromadex.com/...html?c=212121&p=irol-stockquote

is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model which utilizes its wholly-owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as “phytochemicals”), chemistry and analytical testing services  and product regulatory and safety consulting (as Spherix Consulting).  The Company provides seamless science-based solutions to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries. Our ingredient technologies unit includes products backed with extensive scientific research and intellectual property. The ingredient portfolio includes pTeroPure® pterostilbene; ProC3G™, a natural black rice containing cyanidin-3-glucoside; PURENERGY™, a caffeine-pTeroPure co-crystal; nutraGac™, a gac fruit powder; curcumin, and NIAGEN™, its recently launched branded nicotinamide riboside, a novel next-generation B-vitamin.chromadex.com/About-Us/About-ChromaDex.html

Develops & markets phytochemical and botanical reference standards & materials
Develops & markets novel & natural products that have a positive impact on health
Brings safety & quality to the market with specialized services and scientific rigor
chromadex.com/About-Us/About-ChromaDex.html

to growing demand for natural product reference standards, materials, and services. This growth has continued with increasing consumer and government demand for quality assurance methods across the spectrum of consumer-focused products. chromadex.com/About-Us/About-ChromaDex.html

in the reference standards & services business with a customer-centric approach supported by scientific rigor. Its expertise in this market gives it a unique foundation for combining the power of nature with the science of health to develop & market natural & novel ingredients. chromadex.com/About-Us/About-ChromaDex.html

is publicly-traded company (OTCQB:CDXC).
chromadex.com/About-Us/About-ChromaDex.html

.
...mal nen fixen CHROMADEX ..(Ticker INDEX) ..inside Gruss an Balu4u und buran hier ;-)

..RTK 1,02 € RTP -0,20 Pott +2,15% ,GrB
 

http://www.ariva.de/news/...rch-Institute-for-NIAGEN-Research-5118959 GrB

http://www.ariva.de/news/...nce-on-August-13th-at-8-30-am-EDT-5123813 GrB

http://www.ariva.de/news/...Chemical-Society-National-Meeting-5125666 GrB

http://www.ariva.de/news/...ear-Over-Year-and-52-Sequentially-5131715 GrB

buran: nur ein börsenboard geführt von www.bundesbank.de 21:18 #1
achte er einfach auf die links
Mit freundlichen Grüssen Mario Meierhof 39517 Lüderitz Gartenstrasse 6
mariomeierhof@web.de
Tel.:039361/96548 Atelier Meierhof 039361/51273 Kuhle
gez MARIO alias buran http://www.ariva.de/…/nur-ein-boersenboard-gefuehrt-von-www…

Deutsche Bundesbank - Startseite
Die Deutsche Bundesbank ist die Zentralbank der Bundesrepublik Deutschland. Zentrales Geschäftsfeld ist die Geldpolitik des Eurosystems.
BUNDESBANK.DE
https://www.facebook.com/mario.meierhof

Kosmonova buran

Kosmonova buran

Bezeichnet eine Kurslücke in einem Seitwärtstrend oder Lücken durch geringe Umsätze. Sie sind nicht von Bedeutung und es können keine Aussagen über den weiteren Kursverlauf gemacht werden. http://www.ariva.de/extras/lexikon.m?begriff=common_Gap

Buch dazu
http://www.ariva.de/chromadex_corp-aktie/times_and_sales?boerse_id=83 GrB

..yöah

Preis pro Anteilsschein 1,369 € Schleife 731 spread 10,58% buran und MfG und ditt Leben iss ne Ticker Wolke

Buch dazu
http://www.ariva.de/chromadex_corp-aktie/times_and_sales?boerse_id=83 GrB

Aktien New York: Deutlich fester nach Nike-Zahlen - Dollar und Ölpreise stützen
19:05 20.03.15 http://www.ariva.de/news/...len-Dollar-und-Oelpreise-stuetzen-5316726

COOL!

::pups:::

http://www.ariva.de/news/list.m GrB

http://www.ariva.de/dow-jones-industrial-average-index/news GrB

22:40 08.05.15


Die US-Börsen reagieren erleichtert auf den Bericht vom US-Arbeitsmarkt. Der Durchhänger im letzten Monat war wohl doch keine Trendwende, sondern nur eine Delle. Dow Jones und Co laufen mit deutlichen Aufschlägen. http://www.ariva.de/news/Arbeitsmarkt-treibt-Wall-Street-an-5362650

:::furz::::::::::::::

Datum Erster Hoch Tief Schluss     Stücke Volumen
  02.07.15     1,225      1,25§1,14 1,22 $ 46.476 54 T

GrB

:::::::::::::::: 1,19 $ +2,59% +0,03 $
In Euro: 1,0828 € | Nasdaq OTC Other, 07.07.15 ,GrB

     Datum    Erster      Hoch      Tief§Schluss     Stücke Volumen
  17.08.15     1,195      1,25§1,19 1,25 $ 108.707 133 T

GrB

globenewswire.com/news-release/2015/11/05/...mble-Company.html

NIAGEN® Launches at GNC Stores Nationwide
16:15 21.01.16

PR Newswire

LIGHTHOUSE POINT, Fla., Jan. 21, 2016

LIGHTHOUSE POINT, Fla., Jan. 21, 2016 /PRNewswire/ -- Specialty Nutrition Group, Inc. has announced the release of NIAGEN® in GNC stores nationwide, as part of its innovation partnership with the world's largest retailer of nutrition products.  NIAGEN® will be marketed under the F1RST® brand of patented and research-backed single-ingredient products in GNC stores.

Quelle: PR Newswire

Specialty Nutrition Group, Inc. is a nutrition brand-building firm focused on commercializing innovative, IP-protected nutritional and health-promoting technologies. SNG acts as co-development partner with large consumer products and nutrition companies to rapidly commercialize nutrition innovations, represents academic institutions and individual inventors to find new commercial applications for their inventions, and develops its own brands for launch in targeted commercial markets. More at www.SpecialtyNutrition.com.

Media Contacts:

For Specialty Nutrition Products:

Lisa Pineiro, 954-941-4347, Info@SpecialtyNutritition.com

Logo - photos.prnewswire.com/prnh/20160113/322134LOGO

To view the original version on PR Newswire, visit:www.prnewswire.com/news-releases/...-nationwide-300207265.html

SOURCE Specialty Nutrition Group, Inc.


Quelle: PR Newswire

:::::::::::::: 1,365 $ +2,02% +0,027 $
In Euro: 1,2233 € | Nasdaq OTC Other, 05.02.16  ,GrB

http://www.ariva.de/news/...n-NAD-in-College-Football-Players-5713631 GrB

WKN: A0YHDH  ISIN: US1710771007  Symbol: CDXC Typ: Aktie ,GrB
 

kein aktueller Kurs verfügbar ,GrB

kein aktueller Kurs verfügbar ,GrB

Beiträge: 63
Zugriffe: 6.288 / Heute: 2

GrB